JPWO2021071788A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021071788A5
JPWO2021071788A5 JP2022520976A JP2022520976A JPWO2021071788A5 JP WO2021071788 A5 JPWO2021071788 A5 JP WO2021071788A5 JP 2022520976 A JP2022520976 A JP 2022520976A JP 2022520976 A JP2022520976 A JP 2022520976A JP WO2021071788 A5 JPWO2021071788 A5 JP WO2021071788A5
Authority
JP
Japan
Prior art keywords
composition according
composition
oligonucleotides
c9orf72
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550915A (ja
Publication date
Priority claimed from PCT/US2020/032244 external-priority patent/WO2020227691A2/en
Application filed filed Critical
Priority claimed from PCT/US2020/054307 external-priority patent/WO2021071788A2/en
Publication of JP2022550915A publication Critical patent/JP2022550915A/ja
Publication of JPWO2021071788A5 publication Critical patent/JPWO2021071788A5/ja
Pending legal-status Critical Current

Links

JP2022520976A 2019-10-06 2020-10-05 オリゴヌクレオチド組成物及びその使用方法 Pending JP2022550915A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962911340P 2019-10-06 2019-10-06
US62/911,340 2019-10-06
US202062983736P 2020-03-01 2020-03-01
US62/983,736 2020-03-01
PCT/US2020/032244 WO2020227691A2 (en) 2019-05-09 2020-05-08 Oligonucleotide compositions and methods of use thereof
USPCT/US2020/032244 2020-05-08
US202063069704P 2020-08-24 2020-08-24
US63/069,704 2020-08-24
PCT/US2020/054307 WO2021071788A2 (en) 2019-10-06 2020-10-05 Oligonucleotide compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022550915A JP2022550915A (ja) 2022-12-05
JPWO2021071788A5 true JPWO2021071788A5 (enrdf_load_stackoverflow) 2024-01-11

Family

ID=75438309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520976A Pending JP2022550915A (ja) 2019-10-06 2020-10-05 オリゴヌクレオチド組成物及びその使用方法

Country Status (12)

Country Link
US (1) US20240175016A1 (enrdf_load_stackoverflow)
EP (1) EP4037695A4 (enrdf_load_stackoverflow)
JP (1) JP2022550915A (enrdf_load_stackoverflow)
KR (1) KR20220070324A (enrdf_load_stackoverflow)
CN (1) CN114585370A (enrdf_load_stackoverflow)
AU (1) AU2020363344A1 (enrdf_load_stackoverflow)
BR (1) BR112022006207A2 (enrdf_load_stackoverflow)
CA (1) CA3156176A1 (enrdf_load_stackoverflow)
IL (1) IL291974A (enrdf_load_stackoverflow)
MX (1) MX2022004102A (enrdf_load_stackoverflow)
TW (1) TW202126810A (enrdf_load_stackoverflow)
WO (1) WO2021071788A2 (enrdf_load_stackoverflow)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
WO2017210647A1 (en) 2016-06-03 2017-12-07 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
AU2017281497B2 (en) 2016-06-22 2023-04-06 Proqr Therapeutics Ii B.V. Single-stranded RNA-editing oligonucleotides
PL3507366T3 (pl) 2016-09-01 2021-05-04 Proqr Therapeutics Ii B.V. Chemicznie modyfikowane jednoniciowe oligonukleotydy edytujące rna
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CN110997692B (zh) 2017-06-02 2025-01-07 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
CN111051281A (zh) 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法
KR20200035301A (ko) 2017-08-08 2020-04-02 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 방법
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
WO2019075357A1 (en) 2017-10-12 2019-04-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
CN112218664A (zh) 2018-05-11 2021-01-12 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
AR131145A1 (es) 2022-11-24 2025-02-19 Proqr Therapeutics Ii Bv Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2856403T3 (es) * 2014-03-18 2021-09-27 Univ Massachusetts Composiciones a base de rAAV y procedimientos para el tratamiento de la esclerosis lateral amiotrofica
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
HUE049233T2 (hu) * 2015-04-16 2020-09-28 Ionis Pharmaceuticals Inc C9ORF72-expresszió módosítására szolgáló készítmények
TW201722439A (zh) * 2015-10-09 2017-07-01 波濤生命科學有限公司 寡核苷酸組合物及其方法
US11260073B2 (en) * 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
KR20200035301A (ko) * 2017-08-08 2020-04-02 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 방법
CN114502177A (zh) * 2019-05-09 2022-05-13 波涛生命科学有限公司 寡核苷酸组合物及其使用方法

Similar Documents

Publication Publication Date Title
JPWO2021071788A5 (enrdf_load_stackoverflow)
JPWO2020227691A5 (enrdf_load_stackoverflow)
JP2020534253A5 (enrdf_load_stackoverflow)
JPWO2021178237A5 (enrdf_load_stackoverflow)
US20230220393A1 (en) METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
JP2023078293A5 (enrdf_load_stackoverflow)
JP2024009824A5 (enrdf_load_stackoverflow)
CA3156176A1 (en) Oligonucleotide compositions and methods of use thereof
CA3139513A1 (en) Oligonucleotide compositions and methods of use thereof
JP2023145620A5 (enrdf_load_stackoverflow)
DE60132170T2 (de) MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN
CA3072076A1 (en) Oligonucleotide compositions and methods thereof
JP2018525357A5 (enrdf_load_stackoverflow)
JP2009532392A5 (enrdf_load_stackoverflow)
CA2453301A1 (en) Synthetic double-stranded oligonucleotides for specific inhibition of gene expression
JP7690979B2 (ja) 一本鎖オリゴヌクレオチド
JPWO2019217784A5 (enrdf_load_stackoverflow)
CA2989682A1 (en) Oligonucleotide compositions and methods thereof
RU2015104762A (ru) Хиральный контроль
WO1995017507A1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
JP2021500013A (ja) B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子
JP2006141402A5 (enrdf_load_stackoverflow)
WO2021157730A1 (ja) 核酸医薬とその使用
EP3677680A1 (en) Small guide antisense nucleic acid and use thereof
TW390884B (en) Chirally enriched synthetic phosphonate oligomers